TITLE

Melatonin improves abdominal pain in irritable bowel syndrome patients who have sleep disturbances: a randomised, double blind, placebo controlled study

AUTHOR(S)
Song, G. H.; Leng, P. H.; Gwee, K. A.; Moochhala, S. M.; Ho, K. Y.
PUB. DATE
October 2005
SOURCE
Gut;Oct2005, Vol. 54 Issue 10, p1402
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: Melatonin, a sleep promoting agent, is involved in the regulation of gastrointestinal motility and sensation. We aimed to determine if melatonin was effective in improving bowel symptoms and sleep disturbances in irritable bowel syndrome (IBS) patients with sleep disturbance. Methods: Forty IBS patients (aged 20-64 years; 24 female) with sleep disturbances were randomly assigned to receive either melatonin 3 mg (n = 20) or matching placebo (n = 20) at bedtime for two weeks. Immediately before and after the treatment, subjects completed bowel, sleep, and psychological questionnaires, and underwent rectal manometry and overnight polysomnography. Results: Compared with placebo, melatonin taken for two weeks significantly decreased mean abdominal pain score (2.35 v 0.70; p<0.001) and increased mean rectal pain threshold (8.9 v - 1.2 mm Hg; p<0.01). Bloating, stool type, stool frequency, and anxiety and depression scores did not significantly differ after treatment in both groups. Data from sleep questionnaires and polysomnography showed that the two week course of melatonin did not influence sleep parameters, including total sleep time, sleep latency, sleep efficiency, sleep onset latency, arousals, duration of stages 1-4, rapid eye movement (REM) sleep, and REM onset latency. Conclusions: Administration of melatonin 3 mg at bedtime for two weeks significantly attenuated abdominal pain and reduced rectal pain sensitivity without improvements in sleep disturbance or psychological distress. The findings suggest that the beneficial effects of melatonin on abdominal pain in IBS patients with sleep disturbances are independent of its action on sleep disturbances or psychological profiles.
ACCESSION #
18457686

 

Related Articles

  • Effect of Ramelteon, a selective MT1/MT2-receptor agonist, on respiration during sleep in mild to moderate COPD. Meir Kryger; Sherry Wang-Weigand; Jeffrey Zhang; Thomas Roth // Sleep & Breathing;Aug2008, Vol. 12 Issue 3, p243 

    Abstract  Ramelteon, a selective MT1/MT2 melatonin receptor agonist, was evaluated in subjects with mild to moderate chronic obstructive pulmonary disease (COPD) to determine whether it would have a negative effect on measures of safety and respiration. This randomized, double-blind,...

  • Melatonin for irritable bowel syndrome. Gaby, Alan R. // Townsend Letter;Feb/Mar2006, Issue 271/272, p32 

    The article comments on a study addressing the use of melatonin or placebo in irritable bowel syndrome and sleep disturbances. The author cited that melatonin significantly decreased the mean abdominal pain. It has demonstrated the supplementation of melatonin with three milligram of melatonin...

  • Psychological Distress Is Linked to Gastrointestinal Symptoms in Diabetes Mellitus. Talley, Nicholas J.; Bytzer, Peter; Hammer, Johann; Young, Lisa; Jones, Michael; Horowitz, Michael // American Journal of Gastroenterology;Apr2001, Vol. 96 Issue 4, p1033 

    OBJECTIVE: Gastrointestinal (GI) symptoms are common in patients with long-standing diabetes mellitus, but the pathogenesis is controversial. We aimed to determine if GI symptoms are linked to psychological distress in diabetes. METHODS: A consecutive sample of outpatients with diabetes mellitus...

  • Dienogest.  // Reactions Weekly;10/1/2011, Issue 1371, p15 

    The article describes the case of five women who developed metrorrhagia, abdominal pain, depression and hot flashes during treatment with oral dienogest.

  • BrainCells reports encouraging results from depression trial.  // PharmaWatch: CNS;Sep2009, Vol. 8 Issue 9, p19 

    The article presents a study which evaluates the efficacy of BCI-952 for major depressive disorders (MDD) treatment. BCI-952 is a combination of low dose buspirone and melatonin. The study was participated by 142 patients in six weeks period, where BCI-952 showed improvements in multiple...

  • Placebo-controlled studies in depression: necessary, ethical and feasible. Baldwin, David; Broich, Karl; Fritze, Jürgen; Kasper, Siegfried; Westenberg, Herman; Möller, Hans-Jürgen // European Archives of Psychiatry & Clinical Neuroscience;2003, Vol. 253 Issue 1, p22 

    Placebo-controlled trials are used widely in the development of new pharmacological treatments. They have sometimes been challenged as being unethical, in clinical situations where patients can receive an existing effective and acceptable treatment. It has been argued that studies of potential...

  • Sleep-promoting properties of quetiapine in healthy subjects Quetiapine and sleep. Cohrs, Stefan; Rodenbeck, Andrea; Guan, Zhenghua; Pohlmann, Kathrin; Jordan, Wolfgang; Meier, Andreas; Rüther, Eckart // Psychopharmacology;2004, Vol. 174 Issue 3, p421 

    The aim of this study was to investigate the effects of quetiapine, an atypical antipsychotic, on polysomnographic sleep structure and subjective sleep quality. This double-blind, placebo-controlled, randomized cross-over study investigated the polysomnographic sleep structure and subjective...

  • Drug information update: agomelatine. Whiting, Daniel; Cowen, Philip J. // Psychiatrist;Nov2013, Vol. 37 Issue 11, p356 

    Agomelatine is a new antidepressant, licensed for the treatment of unipolar major depression, with a mode of action that combines activation of melatonin receptors with blockade of 5HT2C receptors. Agomelatine is notable for its short duration of action in the body and modest side-effect burden;...

  • Agomelatine: A Preliminary Review of a New Antidepressant. Zupancic, Michael; Guilleminault, Christian // CNS Drugs;2006, Vol. 20 Issue 12, p981 

    Agomelatine is a new antidepressant that is a potent agonist of melatonin receptors and an antagonist of the serotonin 5-HT2C receptor subtype. It is in late-phase trials for the treatment of major depressive disorder (MDD).Symptoms of depression significantly improved with agomelatine compared...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics